Ototoxicity of cisplatin

Abstract

Ototoxicity is one of the unwanted side effects of cisplatin treatment. The first sign of hearing loss usually appears 3-4 days after the drug administration and occurs primarily in the higher frequencies. One hundred and eighty-six women treated with a moderate dose of cisplatin (50 mg/m2 every 4 weeks) for gynaecological cancer were studied. No significant loss of hearing was detected in the speech frequency range. Since the cisplatin concentration in the inner ear is highest after a single high dose injection, systemic audiometric monitoring is advisable during cisplatin therapy with single high dose regimen.